Question is, at what price? AMLN looks cheap here and vulnerable. With the current sentiment of takeovers in biotech its a credible possibility, but not one I'm hoping for. Once approved, this drug should generate tremendous revenue.
hmmmm, at what price??? If a takeover attempt by another Pharma were to occur soon, I believe it would be in the low 20's with Lilly bidding it to the upper 20's..... Amln does look very very cheap, and this management team is much more than vulnerable.... imho
I would certainly hope that Carl Ichan is talking... just not to Lilly but to the likes of Roche, J&J, BMY or Pfizer... A major pharma that certainly recognizes the incredible opportunity with Bydureon, and can take Symlin to the next level, and knows how to work the regulatory process, has an effective PR arm, plus sees promise on the obesity front, likes the new plant and the cash on hand and also recognizes that there is significant value in the R&D of future frontiers for Exenatide... One pretty much can forcast that would force Lilly's hand in bidding for the company...
ok neighbor We get it.You are in and hope for a buyout.
Before the crash,Icahn was averaged in around 20.
We do not know if he was short,sold or bought some cheap because there were 51 Million shares traded on the 20th.IF Lilly gets amln for cheap,one will always wonder if this was collusion by others or incompetence by management- or both. The FDA decision seems almost unbelievable given what we know.